STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals, Inc. - NRXP STOCK NEWS

Welcome to our dedicated page for NRX Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals stock.

NRX Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage, small-molecule pharmaceutical company dedicated to developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company's flagship products include ZYESAMI (Aviptadil), aimed at treating COVID-related respiratory failure, and NRX-100/101, the first sequential drug regimen specifically designed for bipolar depression in patients with acute suicidal ideation and behavior.

Recently, NRX Pharmaceuticals announced a public offering of its common stock to raise funds for working capital, general corporate purposes, and to repay certain debts. The proceeds will also support the initiation of a national treatment protocol and a safety database.

Among its most notable developments, the company is advancing NRX-101, designated as an FDA Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX Pharmaceuticals has strategic partnerships with Alvogen and Lotus for the development and marketing of NRX-101.

The company also oversees Hope Therapeutics, focusing on the development and marketing of IV ketamine for the acute treatment of suicidality and depression, leveraging a digital therapeutic-enabled platform to augment clinical benefits.

NRX Pharmaceuticals' robust pipeline includes plans for a New Drug Application for HTX-100 (IV ketamine) based on promising clinical trial results. It has also received Fast Track Designation from the FDA for the development of ketamine as part of its treatment protocol for acute suicidality.

Furthermore, NRX Pharmaceuticals is exploring the use of NRX-101 for chronic pain and complicated UTI, marking its potential to address significant unmet medical needs across various therapeutic areas. The company remains committed to improving patient outcomes and advancing its innovative therapies through rigorous clinical trials and strategic collaborations.

News

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) announced new data on NRX-101 showing no damage to intestinal and vaginal flora in rodent models, potentially avoiding C. difficile infections. NRX-101 has FDA QIDP and Fast Track Designation for cUTI and Pyelonephritis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.79%
Tags
none
-
News

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

Rhea-AI Summary
NRx Pharmaceuticals (NASDAQ:NRXP) announced the development of a new, proprietary formulation of IV Ketamine, HTX-100. The formulation achieves a pH-neutral state, enabling both intravenous and subcutaneous administration. The company expects patent protection and has partnered with Nephron Pharmaceuticals to generate patents. HTX-100 is set to be marketed by HOPE Therapeutics, a subsidiary of NRx.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.3%
Tags
none
-
News

NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

Rhea-AI Summary
NRx Pharmaceuticals achieves data-lock in Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101, anticipates top-line data release in April 2024. Positive results lead to additional milestone payments and future development costs covered by partners. NRX-101 demonstrates potential for a broader patient population, with FDA designations and successful trials positioning it as a promising therapy for suicidal bipolar depression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
clinical trial
News

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
NRx Pharmaceuticals, Inc. announced significant milestones for 2024, including clinical trial data, NDA filing, share dividend, and commercial revenue forecasts. The company reported a 50% reduction in corporate overhead, 25% reduction in net loss, and an improvement in negative earnings per share. Key partnerships and advancements in NRX-101 development for bipolar depression, chronic pain, and urinary tract infection were highlighted. The company also established HOPE Therapeutics for IV Ketamine, with positive financial results and working capital additions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.23%
Tags
earnings
-
News

NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights

Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces anticipated financial results for FY 2023, highlighting improved negative EPS, positive cash flow projections by 2024, reduction in corporate indebtedness, key partnerships with Alvogen and Lotus Pharmaceuticals, successful clinical trial data for NRX-101 in bipolar depression, positive outcomes in ketamine studies, and plans for NDA filings and share dividends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags
earnings
-
News

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will undergo a reverse stock split on April 1, 2024, where every 10 pre-split shares will convert to 1 post-split share. The split-adjusted common stock will trade under the symbol NRXP on the Nasdaq Capital Market starting April 2, 2024. The reverse split aims to align share price with institutional investor preferences and enhance long-term shareholder value. Positive clinical trial data and future developments indicate potential for a forward stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.94%
Tags
stock split
News

UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) to release Q4 and full year 2023 financial results on March 28, 2024. Conference call rescheduled to April 1, 2024, due to Good Friday holiday. Webcast and dial-in options available for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
conferences earnings
-
News

NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announced Dr. Jonathan Javitt will present at the Ketamine 2024 Conference in Oxford, UK. The conference gathers leading scientists and clinicians worldwide to share knowledge and insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
-
News

NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024

Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will release its Q4 and full year 2023 financial results on March 28, 2024. A conference call to discuss the results and provide a corporate update will be held at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.89%
Tags
conferences earnings
News

NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders

Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces the results of a Special Meeting of Shareholders with 61.4% of eligible shares voted, 94.4% in favor of a proposal for a reverse stock split. Despite efforts to suppress the vote, shareholders showed overwhelming support for the resolution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none

FAQ

What is the current stock price of NRX Pharmaceuticals (NRXP)?

The current stock price of NRX Pharmaceuticals (NRXP) is $1.23 as of November 21, 2024.

What is the market cap of NRX Pharmaceuticals (NRXP)?

The market cap of NRX Pharmaceuticals (NRXP) is approximately 14.6M.

What is NRX Pharmaceuticals' primary focus?

NRX Pharmaceuticals focuses on developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases.

What are NRX Pharmaceuticals' key products?

The key products include ZYESAMI (Aviptadil) for COVID-related respiratory failure and NRX-100/101 for bipolar depression with acute suicidal ideation.

What is the significance of NRX-101?

NRX-101 is an FDA-designated Breakthrough Therapy aimed at treating suicidal treatment-resistant bipolar depression and chronic pain.

Who are NRX Pharmaceuticals' strategic partners?

NRX Pharmaceuticals has partnered with Alvogen and Lotus for the development and marketing of NRX-101.

What recent developments has NRX Pharmaceuticals announced?

The company has announced a public offering to raise funds for working capital, initiating a national treatment protocol, and repaying debts.

What is Hope Therapeutics?

Hope Therapeutics is a subsidiary of NRX Pharmaceuticals, focusing on the development and marketing of FDA-approved intravenous ketamine for acute suicidality and depression.

What is the purpose of the public offering announced by NRX Pharmaceuticals?

The public offering aims to raise funds for working capital, general corporate purposes, and to repay certain outstanding debts.

What are the future plans for NRX-101?

NRX Pharmaceuticals plans to expand NRX-101’s use for chronic pain and complicated UTI, and potentially submit a New Drug Application based on clinical trial results.

Has NRX Pharmaceuticals received any special designations from the FDA?

Yes, NRX Pharmaceuticals has received Fast Track Designation from the FDA for the development of ketamine (NRX-100) as part of its treatment protocol for acute suicidality.

What is the financial condition of NRX Pharmaceuticals as of the latest update?

As of the latest update, NRX Pharmaceuticals is in the process of raising funds through a public offering and has received $5 million from a milestone payment, improving its working capital situation.

Stock NRXP logo
NRX Pharmaceuticals, Inc.

Nasdaq:NRXP

NRXP Rankings

#5415 Ranked by Market Cap
N/A Ranked by Dividends

NRXP Stock Data

14.63M
9.24M
23.56%
6.05%
6.35%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WILMINGTON